

1 SARS-CoV-2 antigens expressed in plants detect antibody responses in 2 COVID-19 patients

3

4 Mohau S. Makatsa^{1,2†}, Marius B. Tincho^{1,2†}, Jerome M. Wendoh^{1,2†}, Sherazaan D. Ismail^{1,2},
5 Rofhiwa Nesamari^{1,2}, Francisco Pera³, Scott de Beer³, Anura David⁴, Sarika Jugwanth⁵,
6 Maemu P. Gededzha⁵, Nakampe Mampeule⁵, Ian Sanne⁶, Wendy Stevens⁴, Lesley Scott⁴,
7 Jonathan Blackburn^{1,7}, Elizabeth S. Mayne⁵, Roanne S. Keeton^{1,2}, Wendy A. Burgers^{1,2,8*}

8

9 ¹Institute of Infectious Disease and Molecular Medicine, and ²Division of Medical Virology,
10 Department of Pathology, University of Cape Town, Cape Town, South Africa; ³Cape Bio
11 Pharms, Cape Town, South Africa; ⁴Department of Molecular Medicine and Haematology,
12 University of Witwatersrand, Johannesburg, South Africa; ⁵Department of Immunology,
13 Faculty of Health Sciences, University of Witwatersrand and National Health Laboratory
14 Service Johannesburg, South Africa; ⁶Clinical HIV Research Unit, Department of Internal
15 Medicine, University of Witwatersrand, Johannesburg, South Africa; ⁷Division of Chemical
16 and Systems Biology, Department of Integrative Biomedical Sciences, University of Cape
17 Town, Cape Town, South Africa; ⁸Wellcome Centre for Infectious Diseases Research in
18 Africa, University of Cape Town, Cape Town, South Africa.

19

20 ***Corresponding author:** Wendy Burgers, Institute of Infectious Disease and Molecular
21 Medicine, Faculty of Health Sciences, University of Cape Town, Observatory 7925, South
22 Africa; Phone: +27-21-4066090; (wendy.burgers@uct.ac.za).

23

24 [†]M.S.M., M.B.T. and J.M.W. contributed equally to this work.

25

26 Manuscript information:

27 Running title: SARS-CoV-2 ELISA using plant-produced proteins

28 Abstract: 341 words; Manuscript word count: 4522; Figures: 6, Tables: 1

29 Keywords: SARS-CoV-2, COVID-19, serology, ELISA, plant expression

30

31 **Funding:** This work was supported by the Wellcome Centre for Infectious Diseases Research
32 in Africa (CIDRI-Africa), which is supported by core funding from the Wellcome Trust
33 [203135/Z/16/Z]. Sample collection was funded through the EQUIP grant AID-OAA-A-15-
34 00070- Antiretroviral Therapy Simplification-Optimization of Programs and Services (ART-
35 OPS) COVID supplement and through iLEAD BMGF (i-LEAD) grant ID OPP1171455. The
36 funders had no role in study design, data collection and analysis, decision to publish, or
37 preparation of the manuscript. The views expressed are those of the authors, and the funders
38 are not responsible for any use that may be made of the information contained herein.

39

40 **Declaration of interests:** Francisco Pera and Scott de Beer are employed by Cape Bio Pharms.
41 The remaining authors declare that the research was conducted in the absence of any
42 commercial or financial relationships that could be construed as a potential conflict of interest.

43

44 **Acknowledgements:** We thank Tamlyn Shaw of Cape Bio Pharms. We also thank Markus
45 Sack from Pro-SPR GmbH, Alsdorf, Germany for his assistance in designing the S1 and RBD
46 genes. We thank Muneerah Smith for inactivation and aliquoting of samples. We thank the
47 study participants for providing samples. We are immensely grateful to Florian Krammer and
48 his laboratory at Icahn School of Medicine at Mount Sinai, USA, for rapidly sharing their
49 reagents, protocols and results with the scientific community, and being a model of what our
50 science should be openly accessible and in the service of humankind.

51

52 **Author contributions:** Conceived and designed the study and experiments: WAB, MSM,
53 MBT, JMW, FP, SdB, ESM, LS and JB. Provided support and critical protocol review: WS,
54 IS. Performed the experiments: MSM, MBT, JMW, AD, SJ, NM, MG, FP, SdB. Analyzed the
55 data: MSM, AD, SJ, NM, MG, SDI, RN, RSK and WAB. Wrote the paper: FP, SDI, RN, RSK,
56 MBT, JMW, MSM and WAB. All authors approved the final manuscript.

57

58 **Contribution to the Field Statement**

59 The SARS-CoV-2 pandemic poses a significant global threat to lives and livelihoods, with over
60 16 million confirmed cases and at least 650 000 deaths from COVID-19 in the first 7 months
61 of the pandemic. Developing tools to measure antibody responses and understand protective
62 immunity to SARS-CoV-2 is a priority. Many expression systems exist to produce the proteins
63 required in the establishment of these serological assays, but plant-based systems have several
64 advantages over more widely used conventional protein expression systems. Most notably, they
65 are rapid, scaleable and cost-effective, making them attractive protein expression systems
66 particularly in low-income settings such as ours in Africa. We were able to develop a cost-
67 effective serological assay by making use of plant-produced viral antigens. Our study
68 demonstrates that recombinant SARS-CoV-2 proteins produced in plants enable the robust
69 detection of SARS-CoV-2-specific antibodies equivalent to that observed in a high sensitivity
70 commercial assay in which antigens were produced in a mammalian expression system. Our
71 ELISA can be used to evaluate SARS-CoV-2 seroprevalence, describe the kinetics of the
72 humoral immune response in infected individuals, and investigate humoral immunity in our
73 setting where comorbidities are highly prevalent.

74 Abstract

75 **Background:** The SARS-CoV-2 pandemic has swept the world and poses a significant global
76 threat to lives and livelihoods, with over 16 million confirmed cases and at least 650 000 deaths
77 from COVID-19 in the first 7 months of the pandemic. Developing tools to measure
78 seroprevalence and understand protective immunity to SARS-CoV-2 is a priority. We aimed
79 to develop a serological assay using plant-derived recombinant viral proteins, which represent
80 important tools in less-resourced settings.

81
82 **Methods:** We established an indirect enzyme-linked immunosorbent assay (ELISA) using the
83 S1 and receptor-binding domain (RBD) portions of the spike protein from SARS-CoV-2,
84 expressed in *Nicotiana benthamiana*. We measured antibody responses in sera from South
85 African patients (n=77) who had tested positive by PCR for SARS-CoV-2. Samples were taken
86 a median of six weeks after the diagnosis, and the majority of participants had mild and
87 moderate COVID-19 disease. In addition, we tested the reactivity of pre-pandemic plasma
88 (n=58) and compared the performance of our in-house ELISA with a commercial assay. We
89 also determined whether our assay could detect SARS-CoV-2-specific IgG and IgA in saliva.

90
91 **Results:** We demonstrate that SARS-CoV-2-specific immunoglobulins are readily detectable
92 using recombinant plant-derived viral proteins, in patients who tested positive for SARS-CoV-
93 2 by PCR. Reactivity to S1 and RBD was detected in 51 (66%) and 48 (62%) of participants,
94 respectively. Notably, we detected 100% of samples identified as having S1-specific antibodies
95 by a validated, high sensitivity commercial ELISA, and OD values were strongly and
96 significantly correlated between the two assays. For the pre-pandemic plasma, 1/58 (1.7%) of
97 samples were positive, indicating a high specificity for SARS-CoV-2 in our ELISA. SARS-
98 CoV-2-specific IgG correlated significantly with IgA and IgM responses. Endpoint titers of
99 S1- and RBD-specific immunoglobulins ranged from 1:50 to 1:3200. S1-specific IgG and IgA
100 were found in saliva samples from convalescent volunteers.

101
102 **Conclusions:** We demonstrate that recombinant SARS-CoV-2 proteins produced in plants
103 enable robust detection of SARS-CoV-2 humoral responses. This assay can be used for
104 seroepidemiological studies and to measure the strength and durability of antibody responses
105 to SARS-CoV-2 in infected patients in our setting.

106 Introduction

107 The current global pandemic, caused by the novel severe acute respiratory syndrome
108 coronavirus 2 (SARS-CoV-2), has resulted in over 16 million cases and at least 650 000 deaths,
109 as of 27 July 2020. SARS-CoV-2 was first detected in December 2019 in Wuhan, a city in the
110 Hubei province of China, and is thought to originate from zoonotic transmission of a bat
111 coronavirus (Tan et al., 2020; Zhu et al., 2020). Coronavirus disease 2019 (COVID-19), the
112 resultant disease, is commonly associated with fever, cough and fatigue, and in severe cases,
113 pneumonia and respiratory failure (Chan et al., 2020).

114 SARS-CoV-2 is a 30kB positive-stranded RNA virus that is a member of the
115 *Betacoronavirus* genus and the subgenus *Sarbecovirus* (Letko et al., 2020). The genus harbours
116 human pathogens that cause respiratory infections, namely the highly virulent SARS-CoV and
117 Middle East respiratory syndrome coronavirus (MERS-CoV), as well as the circulating
118 ‘common cold’ human coronavirus (hCoV)-OC43 and hCoV-HKU1 (Su et al., 2016).
119 Betacoronaviruses express four essential structural proteins, namely the spike (S) glycoprotein,
120 membrane (M) protein, envelope (E) protein and nucleocapsid (N) protein, as well as multiple
121 accessory and non-structural proteins (Neuman et al., 2011, Lu et al., 2020). The S glycoprotein
122 is a homotrimer that protrudes from the surface of the viral particles (Tortorici and Velesler,
123 2019), and interacts with the human cell receptor angiotensin converting enzyme 2 (ACE2)
124 through the receptor-binding domain (RBD), gaining viral entry into the host cell (Li 2016;
125 Letko et al., 2020; Walls et al., 2020). S is cleaved by host cell proteases into two subunits: the
126 S1 subunit which harbours the RBD and enables binding to host cell receptors, and the S2
127 subunit that is important for fusion with the host cell membrane (Walls et al., 2020; Wrapp et
128 al., 2020).

129 The S1 subunit is highly immunogenic, and its RBD portion is the main target of
130 neutralizing antibodies, thus becoming the focus of serological studies (Amanat et al., 2020;
131 Huang et al., 2020; Liu et al., 2020; Okba et al., 2020). Recently, potent neutralizing antibodies
132 isolated from the convalescent sera of SARS-CoV-2 patients were demonstrated to be
133 protective against disease from high-dose SARS-CoV-2 challenge in a small animal model
134 (Rogers et al., 2020), suggesting the potential for therapeutic interventions as well as inferring
135 that recovered SARS-CoV-2 patients may be afforded protection from re-infection by
136 neutralizing antibody responses. Amanat et al (2020) showed a strong correlation between the
137 neutralizing antibody response and ELISA endpoint titers against S, suggesting the use of
138 serological assays in estimating the percentage of infected people who have neutralizing
139 antibodies that protect them from re-infection or disease.

140 Serological assays that can detect antibody responses to SARS-CoV-2 are critical for
141 answering pressing questions regarding immunity to the virus. It is not known what proportion
142 of infected individuals elicit antibodies to SARS-CoV-2, if antibodies serve as correlates of
143 protection, and if so, what the threshold of binding or neutralizing titers are that will provide
144 immunity, and the duration of these responses. Serological assays such as enzyme-linked
145 immunosorbent assays (ELISA) can assist in answering these questions. These assays need to
146 be both sensitive as well as demonstrate high specificity for SARS-CoV-2, and not give false
147 positives due to cross-reactivity with widely circulating hCoVs NL63, 229E, OC43, and
148 HKU1. While the N protein is more conserved among coronaviruses, the S protein sequence
149 has lower sequence conservation. The S1 portion is 21-25% identical at the amino acid level
150 to circulating hCoVs (Okba et al., 2020). Thus, serological assays using the full-length S
151 protein, S1 subunit or RBD portion as antigens have shown good specificity with little cross-

152 reactivity to NL63 and 229E (Amanat et al., 2020; Zhao et al., 2020) compared to the use of N
153 protein (Zhao et al., 2020).

154 Purified recombinant proteins are essential for the establishment of serological assays.
155 Numerous protein expression systems exist, each with their own advantages and limitations.
156 These include bacterial, mammalian, yeast, insect and plant-based systems (Shanmugaraj et
157 al., 2020, Yin et al., 2007). Plant-based systems have several advantages over more widely
158 used conventional protein expression systems (Shanmugaraj and Ramalingam, 2014). Most
159 notably, they are rapid, cost-effective and support post-translational modifications similar to
160 mammalian cell systems, making them attractive protein expression systems particularly in
161 low-income settings (Shanmugaraj and Ramalingam, 2014 and 2020; Maliga et al., 2004).
162 Historically, their major disadvantage was low yield (Shanmugaraj et al., 2020), however
163 advances in plant technology, including transient expression systems and viral vectors, have
164 led to improvements in protein yield (Kapila et al., 1997; Shanmugaraj and Ramalingam, 2014;
165 Yamamoto et al., 2018). Additionally, SARS-CoV S1 protein expressed in tomato and tobacco
166 plants demonstrated good immunogenicity in mice (Pogrebnyak et al., 2005). Together, these
167 studies highlight the potential of plant-based expression systems for the development of
168 serological assay reagents as well as vaccines for the current SARS-CoV-2 pandemic.

169 In this study, we describe the development of an ELISA that enables detection of
170 antibodies directed at the S1 subunit and the RBD portion of the SARS-CoV-2 S glycoprotein,
171 generated through a plant-based expression system.

172

173 **Materials and methods**

174 **Recombinant protein cloning and expression**

175 The S1 portion and receptor binding domain (RBD) of the spike protein of SARS-CoV-2
176 Wuhan-Hu-1 isolate (GenBank: MN908947.3) were produced by Cape Bio Pharms, Cape
177 Town, South Africa. Briefly, *Nicotiana benthamiana* codon-optimized DNA encoding S1 and
178 RBD was synthesized commercially (Genscript). Both genes were fused at their C-terminal
179 region to the fragment crystallizable region (Fc) of rabbit IgG1 (Genbank: L29172.1) and
180 subsequently cloned into Cape Bio Pharms' proprietary vector, pCBP2. *Agrobacterium*
181 *tumefaciens* strain GV3101 (pMP90RK) was used to carry agroinfiltration. Growth of
182 recombinant *A. tumefaciens* and vacuum infiltration of *N. benthamiana* plants was performed
183 as described previously (Maclean et al., 2007). Three days post-infiltration, leaves were
184 homogenized in the presence of phosphate buffered saline (PBS) at a 2:1 ratio buffer:leaf
185 material. Cell debris was removed by centrifugation at 10 000 *g* for 10 min at 4°C, and the
186 clarified supernatant was used for expression analyses and purification by Protein A affinity
187 chromatography.

188 For purification, the extract was filtered through a 0.22 µm cellulose nitrate filter
189 (Sartorius) before loading onto a pre-equilibrated 5 ml column packed with POROS
190 MabCapture A resin (Thermo Fisher). The column was then washed with 10 column volumes
191 of wash buffer (PBS, pH 7.5) and bound proteins eluted using elution buffer (0.1 M glycine,
192 pH 2.5). Eluted fractions were captured in 1/10th volume of neutralization buffer (1 M Tris, pH
193 8.5) and then pooled and applied to a 10K molecular weight cutoff (MWCO) Amicon
194 centrifuge tube (Millipore) for buffer exchange against PBS and sample concentration. Mouse
195 anti-rabbit IgG (γ-chain specific) horseradish peroxidase conjugate (1:2500; IgG-HRP, Sigma)

196 was used in a standard SDS-PAGE and western blot analysis to examine purity of the
197 recombinant proteins.

198

199 **Volunteer recruitment and sample collection**

200 Samples were collected from SARS-CoV-2 infected volunteers (n=77) recruited from Gauteng
201 and the Western Cape provinces of South Africa from 10 April 2020 to 26 May 2020.
202 Volunteers had previously undergone a reverse transcriptase polymerase chain reaction (RT-
203 PCR) test for SARS-CoV-2 from an upper respiratory tract (nose/throat) swab collected into
204 viral transport media. Swabs were processed through approved assays in accredited public and
205 private clinical laboratories. Inclusion criteria were age ≥ 18 years and a confirmed positive
206 PCR for SARS-CoV-2 on the national database of the National Health Laboratory Services
207 (NHLS). Of the 77 participants, 34 (44%) had a second positive PCR result recorded within a
208 week after the first positive test. With respect to disease severity, five participants were
209 asymptomatic, 23 had mild disease (characterised by mild upper respiratory tract symptoms),
210 38 had moderate disease (defined by gastrointestinal symptoms or lower respiratory tract
211 symptoms), and two had severe disease (admission to hospital). Serum and saliva samples were
212 collected between 8 and 70 days after the first positive PCR test. Ethical approval for these
213 studies was obtained from the Human Research Ethics Committee (HREC) of the University
214 of Witwatersrand (M200468) and the University of Cape Town (UCT; 210/2020). All
215 participants provided written, informed consent.

216 Pre-pandemic plasma (n=58) was obtained from banked human samples that were
217 collected from participants recruited from Cape Town, South Africa in 2011-2012, from a study
218 protocol approved by the HREC of the University of Cape Town (158/2010). Storage consent
219 was provided by all participants, and approval for use of the samples in this study was obtained
220 from the HREC, UCT. Samples came from participants who were HIV-infected (n=27) or HIV-
221 uninfected (n=31). All participants had tested positive for exposure to *Mycobacterium*
222 *tuberculosis* based on a positive IFN- γ -release assay (QuantiFERON-TB Gold In-Tube), *i.e.*
223 were classified as having latent tuberculosis infection. The median age was 26 years
224 (interquartile range [IQR]: 22-34 years) and 44/58 (76%) were female. All HIV-infected
225 individuals were antiretroviral treatment (ART)-naive, with a median CD4 count of 591
226 cells/mm³ (IQR: 511-749).

227 All samples were treated with 1% Triton-X100 (Sigma) for 60 min at room temperature
228 to inactivate any potentially live virus in the samples (Remy et al., 2019).

229

230 **Enzyme-linked Immunosorbent Assay (ELISA)**

231 The ELISA protocol was adapted from a published protocol (Stadlbauer et al., 2020). Briefly,
232 96-well plates (Nunc MaxiSorp, Thermo Fisher) were coated at 4°C overnight with 50 μ l of
233 varying concentrations (1-4 μ g/ml) of purified recombinant RBD or S1 proteins in PBS or
234 bicarbonate buffer (both Sigma). The following day, plates were washed five times using an
235 automated plate washer and incubated at room temperature in blocking solution (1% casein or
236 3% non-fat powder milk prepared in PBS with 0.1% Tween 20 (PBS-T)). After 1 h, the
237 blocking solution was discarded and 100 μ l of serum, plasma or saliva samples (at 1:50 dilution
238 for sera/plasma and 1:10 for saliva) were added for 2 h at room temperature. Next, plates were

239 washed five times and incubated with goat anti-human IgG (Fc-specific) peroxidase conjugate
240 (1:5000; IgG-HRP, Sigma), or goat anti-human IgA (α -chain specific), F(ab')₂ fragment
241 peroxidase conjugate (1:5000; IgA-HRP, Sigma) or goat anti-human IgM peroxidase conjugate
242 (1:2000; IgM-HRP, Southern Biotech) for 1 h at room temperature. The plate was then
243 developed using 100 μ l O-phenylenediamine dihydrochloride (OPD; Sigma) for 12 min before
244 the reaction was stopped with 50 μ l 3M hydrochloric acid (HCl, Sigma). The plates were read
245 at 490 nm using a Versamax microplate reader (Molecular Devices) using SoftMax Pro
246 software (version 5.3). A cutoff for positivity was set at two standard deviations (SD) above
247 the mean optical density (OD) of pre-pandemic samples. For determining endpoint titers, 2-
248 fold serial dilutions were performed for 20 PCR+ samples and 40 pre-pandemic controls. Area
249 under the curve (AUC) was determined and the positivity threshold was calculated as before,
250 mean+2SD. All patient samples were also analysed using the anti-SARS-CoV-2 ELISA (IgG;
251 Euroimmun), which uses the S1 domain of the spike protein, according to the manufacturer's
252 instructions.

253

254 **Statistical analysis**

255 Statistical analyses were performed in Prism (GraphPad, version 8). Nonparametric tests were
256 used for all comparisons. The Friedman test with Dunn's multiple comparison test was used
257 for matched comparisons; the Mann–Whitney U unmatched and Wilcoxon matched pairs t-
258 tests were used for unmatched and paired samples, respectively. Spearman Rank tests were
259 used for all correlations. AUC was calculated in Prism. A p value of <0.05 was considered
260 statistically significant.

261

262 **Results**

263 **SARS-CoV-2 antigen expression in plants**

264 The S1 and RBD portions of the Spike protein of SARS-CoV-2 were expressed in *Nicotiana*
265 *benthamiana* as fusions to the rabbit IgG Fc tag. Western blot and SDS-PAGE analysis
266 revealed expression of purified S1 (**Figure 1A & B**) and RBD (**Figure 1C & D**) at the expected
267 protein sizes of ~140kDa and ~100kDa, respectively. Higher molecular weight bands of
268 ~280kDa and ~200kDa indicated possible dimer formation of S1 and RBD, respectively. In
269 addition, lower molecular weight bands indicated potentially multiple cleavage products of S1
270 and RBD in the preparations.

271

272 **Participant description**

273 Serum samples were collected from 77 volunteers who had previously tested positive for
274 SARS-CoV-2 by PCR. The demographic and clinical characteristics of the participants are
275 summarized in **Table 1**. Just over half the participants were female, and the median age was
276 39 years. The date of onset of symptoms was not available, but samples were taken a median
277 of 6 weeks after SARS-CoV-2 PCR positivity. The majority of patients (79%) experienced
278 mild or moderate COVID-19 disease. We also included 58 archived plasma samples from HIV-
279 infected and uninfected individuals collected prior to the pandemic (2011-2012) as negative
280 controls for our assay.

281

282 **Plant-produced S1 and RBD proteins are suitable for ELISA detection of SARS-CoV-2** 283 **antibodies**

284 In order to test whether plant-produced SARS-CoV-2 antigens were able to detect virus-
285 specific antibodies from infected patients, we screened convalescent sera from 77 volunteers
286 who had recovered from COVID-19. Individuals were tested for reactivity against both S1 and
287 RBD antigens by a standard indirect ELISA based on a published protocol (Stadlbauer et al.,
288 2020). Archived pre-pandemic plasma samples from 58 individuals, including 27 HIV-infected
289 persons, were used to test the background reactivity to SARS-CoV-2 S1 and RBD. The
290 threshold for positivity was set at two standard deviations above the mean optical density (OD)
291 of the pre-pandemic samples.

292 Of the 77 COVID-19 convalescent serum samples, 51 (66%) tested positive for SARS-
293 CoV-2-specific IgG against S1, and 48 (62%) tested positive against RBD (**Figure 2A & B**).
294 In contrast, only 1/58 pre-pandemic plasma samples showed reactivity above the positivity
295 cutoff. As expected, S1 and RBD IgG OD values correlated strongly ($r=0.977$; $p<0.0001$; data
296 not shown). In order to independently validate our results, the same sera were run in a separate
297 laboratory in a blinded manner, using a commercial IgG ELISA based on S1 antigen from
298 Euroimmun. All samples that were positive by the commercial ELISA test for SARS-CoV-2
299 S1 antibodies were positive in our assay (42/77). We detected nine additional samples that were
300 positive in our assay, two of which had high OD values well above our threshold for positivity,
301 and six that were also positive for RBD-specific IgG. We demonstrated a strong and significant
302 direct correlation for sample OD values between the two assays ($r=0.89$, $p<0.0001$; **Figure**

303 **2C)**. Of note, we found no association between SARS-CoV-2-specific IgG OD values and
304 disease severity or days post PCR positivity (data not shown).

305 Thus, our ELISA using plant-produced recombinant viral proteins performed similarly
306 to a highly sensitive and specific commercial SARS-CoV-2 ELISA.

307

308 **Determination of immunoglobulin titers and isotypes**

309 We next determined the titers of SARS-CoV-2-specific IgG, IgM and IgA responses in a subset
310 of 20 SARS-CoV-2 convalescent serum samples and 40 pre-pandemic samples. Assays were
311 performed on serially diluted samples (**Figure 3A-F**) to determine endpoint titers and AUC
312 values for quantitative interrogation of the data (**Figure 3G-L**). S1-specific IgG was detected
313 in sera of 15/20 individuals (75%), IgM in 13/20 (65%) and IgA in 12/20 (70%) of individuals
314 (**Figure 3G-I**). The median AUCs of IgG, IgM and IgA were significantly higher in
315 convalescent individuals compared to pre-pandemic ($p < 0.0001$ for all). Results for RBD-
316 specific IgG were similar (**Figure 3J-L**). Interestingly, of the five SARS-CoV-2 convalescent
317 sera that tested S1 IgG negative, three had S1-specific IgM and one had S1-specific IgA.
318 Similarly, of the four samples negative for RBD-specific IgG three were positive for IgM and
319 one was double positive for IgM and IgA. Therefore, SARS-CoV-2 S1-specific antibodies were
320 detected in 19/20 convalescent samples and RBD-specific antibodies in 20/20 samples.

321 Further examination of S1-specific antibody isotypes revealed that approximately one
322 third of individuals were positive for IgG, IgM and IgA ($n=7/19$), a smaller proportion has both
323 IgG and IgM or IgG and IgA ($n=3$ and 4 , respectively), while some individuals were positive
324 for only IgG ($n=1$), IgM ($n=3$) or IgA ($n=1$) (**Figure 4A**). RBD-specific isotypes gave similar
325 results (**Figure 4B**). There was a significant correlation between S1-specific IgG and IgM
326 ($r=0.595$, $p < 0.007$; **Figure 4C**) and anti-RBD ($r=0.045$, $p < 0.045$; data not shown). S1-specific
327 IgG showed a trend towards a correlation with IgA ($r=0.423$, $p=0.07$; **Figure 4D**), whilst RBD-
328 specific IgG correlated significantly with IgA ($r=0.635$, $p < 0.003$; data not shown). There was
329 no correlation between IgM and IgA responses for either S1 or RBD (data not shown).

330 Endpoint titers for S1- and RBD-specific IgG, IgM and IgA were determined. S1-
331 specific IgG endpoint titers in 33% of the samples were high (20% at 1:1600 and 13% at 1:800),
332 13% were moderate (1:400) and the majority (54%) of samples had low titers (27% at 1:50,
333 20% at 1:100 and 7% at 1:200) (**Figure 4E**). S1-specific IgA titers were lower than IgG and
334 only 2 individuals have a titer of 1:800 or 1:400 each, and the remaining 84% had low titers
335 ($= < 1:200$; **Figure 4F**). IgM titers for both S1 and RBD were all low ($= < 1:100$; data not
336 shown). RBD-specific titers for IgG and IgM were similar to those S1, with the exception of
337 two donors who had titers of 1:3200 (data not shown).

338

339 **Detection of SARS-CoV-2-specific antibodies in saliva**

340 Given that virus-specific serum antibodies were readily detectable using plant-produced
341 SARS-CoV-2 antigens, we investigated the detection of salivary IgG and IgA using our assay.
342 We compared antibody responses to SARS-CoV-2 antigens in paired saliva and serum from
343 10 participants. In these preliminary analyses, 1/7 samples that had detectable S1-specific
344 serum IgG also demonstrated S1 IgG positivity in saliva (**Figure 5A**). Additionally, 2/5 IgA+

345 sera exhibited virus-specific IgA in saliva. An additional IgA+ sample was detected in saliva
346 but absent from the serum (**Figure 5B**). This indicated that IgA was more readily detectable in
347 saliva than IgG. Further analyses to determine robust thresholds for positivity of saliva
348 immunoglobulins will be performed going forward. These preliminary results demonstrate the
349 potential of our ELISA to detect antibodies to SARS-CoV-2 in saliva.

350

351 **Optimization of the ELISA assay**

352 The in-house ELISA diagnostic assay in this study was developed from the published protocol
353 (Stadlbauer et al., 2020). To determine whether we could further improve the robustness and
354 sensitivity of the in-house ELISA assay, we optimized different parameters, including S1 and
355 RBD antigen coating concentration as well as the coating and blocking buffers. Coating
356 concentrations of 1, 2 and 4 $\mu\text{g}/\text{mL}$ S1 and RBD were compared for SARS-CoV-2-specific IgG
357 detection in four SARS-CoV-2 convalescent volunteers and three pre-pandemic samples. Two
358 and 4 $\mu\text{g}/\text{ml}$ demonstrated a significantly higher reactivity than 1 $\mu\text{g}/\text{ml}$ for both S1 and RBD
359 (**Figure 6A & B**; $p=0.0005$ and $p=0.004$, respectively), with little increase in the background
360 (negative control) signal. Coating of ELISA plates with antigen in different coating buffers,
361 namely PBS and bicarbonate buffer, was also assessed (**Figure 6C**). No differences were
362 detected, so PBS was selected for our procedure. A comparison of the blocking buffers PBS
363 with 0.1% Tween-20 (PBS-T), PBS-T with 1% casein and PBS-T with 3% non-fat milk powder
364 was performed (**Figure 6D**). PBS-T with 1% casein was selected based on background signal
365 and positivity trends.

366 Discussion

367 There is a critical need for the development of serological tests to detect SARS-CoV-2
368 antibodies. Population seroprevalence studies to estimate the extent of pandemic spread in
369 communities, and studies defining protective immunity to SARS-CoV-2, all depend on reliable
370 serological tests. In addition, serological assays are required for the development and
371 evaluation of an effective vaccine. Ideally, such tests need to be cost-effective and easy to scale
372 up to be beneficial in low-income settings. In this study, we describe the establishment of an
373 indirect SARS-CoV-2 antibody ELISA using the S1 and RBD antigens of the spike protein of
374 SARS-CoV-2 expressed in *Nicotiana benthamiana*. S protein domains were selected because
375 they are highly immunogenic and the primary target for neutralizing antibodies (Berry et al.,
376 2010; Chen et al., 2020). Using sera from convalescent volunteers with a PCR-confirmed past
377 SARS-CoV-2 infection, we detected SARS-CoV-2-specific IgG, IgA and IgM to viral S1 and
378 RBD. Our results were highly concordant with a widely used, high sensitivity and specificity
379 commercial S1 IgG ELISA kit (Euroimmun).

380 A range of expression systems exist for the generation of the recombinant proteins
381 required for serological assays. Plant protein expression systems have some advantages over
382 more widely-used mammalian or insect cell systems, as they do not require expensive media
383 or growth conditions (Shanmugaraj et al., 2020). They are also advantageous over bacterial or
384 yeast systems in that they may support post-translational modifications similar to that of
385 mammalian cell lines, and lack contaminating pathogens or endotoxins that pose a problem
386 when purifying desired proteins (Shanmugaraj et al., 2020; Maliga et al., 2004). Lack of correct
387 protein glycosylation and recombinant protein yield are cited as disadvantages to using plants
388 to express protein. However, *Nicotiana benthamiana* is favoured for protein expression due to
389 its rapid generation of biomass, a defective post-transcriptional gene silencing system, and the
390 extensive range of engineering strategies, including glycoengineering, that can be applied along
391 its secretory pathway; all of which may overcome the challenge of low yield (Margolin et al.,
392 2020). Thus, there is great potential to use plant-based expression systems for the rapid
393 generation of serological assay reagents and even vaccines for pandemics, including the current
394 global SARS-CoV-2 pandemic.

395 Using our ELISA with plant-derived recombinant viral proteins, we detected S1-
396 specific IgG in 66.2% and RBD-specific IgG in 62.3% of individuals who had tested positive
397 for SARS-CoV-2 by PCR in the past. Responses between the two protein fragments were
398 highly correlated, as predicted, and the small difference in reactivity was not unexpected, given
399 the greater number of epitopes in the larger S1 domain. Our sensitivity appears lower than that
400 reported in the literature, with a seroprevalence of 90.1%-100% in individuals confirmed to
401 have been SARS-CoV-2-infected by PCR (Amanat et al., 2020; Beavis et al., 2020; Long et
402 al., 2020; Liu et al., 2020), and a lower seroprevalence (65.8%) in those who were diagnosed
403 <14 days before serological testing (Pollán et al., 2020). However, we obtained highly
404 concordant results between our assay and a validated commercial ELISA. In fact, the reported
405 manufacturer's sensitivity of the Euroimmun S1-specific IgG ELISA is 94.4%. This suggests
406 that the lack of S1-specific IgG detection from some recovered COVID-19 patients in our
407 cohort is more likely due to low or absent IgG antibody at the time of sampling, rather than a
408 lack of sensitivity in our assay. With regard to specificity, we detected IgG cross-reactivity to
409 SARS-CoV-2 in 1/58 (1.7%) of pre-pandemic plasma samples from a cohort of HIV-infected
410 and uninfected volunteers with latent TB infection, giving a specificity of 98.3%. Cross-
411 reactive antibody responses, while lower in magnitude, have been reported in SARS-CoV-2
412 unexposed individuals (Khan et al., 2020), and likely result from past infections with common

413 circulating hCoVs. Thus, our assay for SARS-CoV-2-specific IgG performs as well as a widely
414 used commercial kit in terms of sensitivity and specificity, and is suitable for serological studies
415 of humoral responses in the current pandemic.

416 Several factors may affect antibody detection after SARS-CoV-2 exposure. Timing of
417 sampling is important, with IgM typically arising first, peaking two to three weeks after
418 symptom onset (Long et al., 2020). IgG is typically detected after IgM in serum, peaking at
419 roughly the same time (Huang et al., 2020). However, in SARS-CoV-2 infection, antibodies
420 may not follow this typical pattern of seroconversion (Long et al., 2020; Seow et al., 2020) and
421 seroconversion to a single Ig subclass has been described (Seow et al., 2020). Interestingly,
422 when investigating isotype responses in addition to IgG, we showed that a further 4/20 (20%)
423 donors had S1-specific IgA or IgM. Thus, in our initial screen where 34% of individuals who
424 had previously tested positive for SARS-CoV-2 by PCR had no detectable IgG responses, 20%
425 may have had isotype responses other than IgG. A recent study showed that combined detection
426 of IgG, IgM and IgA increased the overall detection of SARS-CoV-2 antibodies, enabling
427 better identification of infected individuals with low antibody levels (Faustini et al., 2020).

428 A further factor in detection of antibodies to SARS-CoV-2 is waning of the response
429 over time, which has potentially important consequences for the duration of protective
430 immunity and the risk of reinfection. One study showed a decrease in IgG in half of patients
431 tested, calculating an overall half-life of 36 days for IgG (Ibarrondo et al., 2020). Waning of
432 binding antibody responses to S and RBD has been reported soon after their peak, particularly
433 IgM and IgA antibodies, but IgG responses have shown persistence for greater than 90 days
434 post-illness onset (Seow et al., 2020; Wajnberg et al., 2020). A limitation of our study was that
435 we did not have information on the date of COVID-19 symptom onset in our cohort, limiting
436 our analyses to time post PCR positivity, which did not yield a relationship with antibody
437 positivity or OD value. Additional factors that may also influence antibody generation and
438 kinetics include disease severity, age and comorbidities. We found no relationship between
439 increasing disease severity and antibody positivity or OD value, likely due to the fact that the
440 majority of our study participants had mild to moderate COVID-19.

441 We determined endpoint titers of binding antibodies to S1 and RBD in a subset of 20
442 convalescent participants in our cohort. Several studies have demonstrated that binding
443 antibody titers against S correlate with neutralization capacity (Amanat et al., 2020; Okba et
444 al., 2020; Premkumar et al., 2020). A recent study reporting S-specific IgG titers in almost 20
445 000 patients screened for eligibility as convalescent plasma donors demonstrated that 70% of
446 IgG+ donors had high titers (>1:960) of antibodies (Wajnberg et al., 2020). Importantly, 100%
447 of those with titers >2880 exhibited neutralizing activity (ID₅₀ of >1:10). Although we
448 performed our study on a much smaller sample size, we detected titers of S1 or RBD-specific
449 IgG of up to 1:3200. However, the majority of donors (54%) had titers below 1:200, and only
450 a third of samples had high titers >1:800. Unsurprisingly, IgA and IgM titers were lower than
451 IgG titers, and did not exceed 1:800 for IgA and 1:400 for IgM. Further studies characterising
452 antibody titers in recovered COVID-19 patients in our setting are warranted.

453 Saliva is a non-invasive specimen that can be self-collected and thus represents an
454 attractive sample type for large-scale sampling such as in seroprevalence studies. We
455 demonstrate that our ELISA can detect SARS-CoV-2-specific IgG and IgA not only in serum,
456 but also in saliva. Further optimization and validation will be required to establish the
457 conditions for optimal detection of antibodies in saliva, including the use of pre-pandemic
458 saliva samples. Recent studies have reported the detection of S-specific antibodies in saliva
459 (Faustini et al., 2020; Randad et al., 2020). Faustini et al. (2020) suggested that the use of both

460 serum and saliva samples increased the detection of SARS-CoV-2 antibody responses,
461 reporting substantial discordance between the two sample types. Although preliminary, our
462 results provide the basis for investigating the detection of SARS-CoV-2 antibodies in saliva
463 using antigens expressed in plants.

464 In conclusion, our study demonstrates that recombinant SARS-CoV-2 proteins
465 produced in plants enable the robust detection of SARS-CoV-2-specific antibodies. One of our
466 aims was to develop a cost-effective serological assay for both large-scale seroepidemiology
467 as well as research studies of SARS-CoV-2 humoral immunity. We achieved this by making
468 use of plants for the production of viral antigens, which has the benefit of rapid scale-up, and
469 sourcing reagents that were available locally and thus available at a lower cost. Our ELISA can
470 be used to evaluate SARS-CoV-2 seroprevalence and describe the kinetics of the humoral
471 immune response in infected individuals. Serological studies in a setting like ours, in South
472 Africa, where comorbidities such as HIV and TB are highly prevalent, are underexplored and
473 can benefit from this assay.

474 **References**

- 475 Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M.,
476 et al. (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat.*
477 *Med.* 26, 1033–1036. doi:10.1038/s41591-020-0913-5.
- 478 Beavis, K. G., Matushek, S. M., Abeleda, A. P. F., Bethel, C., Hunt, C., Gillen, S., et al. (2020).
479 Evaluation of the EUROIMMUN anti-SARS-CoV-2 ELISA assay for detection of IgA
480 and IgG antibodies. *J. Clin. Virol.* 129, 104468. doi:10.1016/j.jcv.2020.104468.
- 481 Berry, J. D., Hay, K., Rini, J. M., Yu, M., Wang, L., Plummer, F. A., et al. (2010). Neutralizing
482 epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure
483 or mAb technology. *MAbs* 2 (1), 53–66. doi:10.4161/mabs.2.1.10788.
- 484 Chan, J. F. W., Yuan, S., Kok, K. H., To, K. K. W., Chu, H., Yang, J., et al. (2020). A familial
485 cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-
486 person transmission: a study of a family cluster. *Lancet* 395(10223), 514-523.
487 doi:10.1016/S0140-6736(20)30154-9.
- 488 Chen, W. H., Hotez, P. J., and Bottazzi, M. E. (2020). Potential for developing a SARS-CoV
489 receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine
490 against coronavirus infectious disease (COVID)-19. *Hum. Vaccines Immunother.* 16 (6),
491 1239-1242. doi:10.1080/21645515.2020.1740560.
- 492 Faustini, S. E., Jossi, S. E., Perez-Toledo, M., Shields, A., Allen, J. D., Watanabe, Y., et al.
493 (2020). Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum
494 and saliva enhances detection of infection. *medRxiv* 2020.06.16.20133025.
495 doi:10.1101/2020.06.16.20133025.
- 496 Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan,
497 S. M., et al. (2020). A systematic review of antibody mediated immunity to
498 coronaviruses: antibody kinetics, correlates of protection, and association of antibody
499 responses with severity of disease. *medRxiv* 2020.04.14.20065771.
500 doi:10.1101/2020.04.14.20065771.
- 501 Ibarondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A.,
502 et al. (2020). Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-
503 19. *N. Engl. J. Med.*, NEJMc2025179. doi:10.1056/NEJMc2025179.
- 504 Kapila, J., De Rycke, R., Van Montagu, M., and Angenon, G. (1997). An Agrobacterium-
505 mediated transient gene expression system for intact leaves. *Plant Sci.* 122(1), 101-108.
506 doi:10.1016/S0168-9452(96)04541-4.
- 507 Khan, S., Nakajima, R., Jain, A., Assis, R. R. de, Jasinskas, A., Obiero, J. M., et al. (2020).
508 Analysis of serologic cross-reactivity between common human coronaviruses and SARS-
509 CoV-2 using coronavirus antigen microarray. *bioRxiv* 2020.03.24.006544.
510 doi:10.1101/2020.03.24.006544.
- 511 Letko, M., Marzi, A., and Munster, V. (2020). Functional assessment of cell entry and receptor
512 usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat. Microbiol.* 5(4),
513 562-569. doi:10.1038/s41564-020-0688-y.

- 514 Li, F. (2016). Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu. Rev.*
515 *Virool.* 3 (1), 237–261. doi:/10.1146/annurev-virology-110615-042301.
- 516 Liu, W., Liu, L., Kou, G., Zheng, Y., Ding, Y., Ni, W., et al. (2020). Evaluation of nucleocapsid
517 and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies
518 against SARS-CoV-2. *J. Clin. Microbiol.* 58(6), e00461-20. doi:/10.1128/JCM.00461-
519 20.
- 520 Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y., et al. (2020a). Antibody
521 responses to SARS-CoV-2 in patients with COVID-19. *Nat. Med.* 26(6), 845–848.
522 doi:10.1038/s41591-020-0897-1.
- 523 Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., et al. (2020). Genomic characterisation and
524 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
525 binding. *Lancet* 395(10224), 565-574. doi:/10.1016/S0140-6736(20)30251-8.
- 526 Maclean, J., Koekemoer, M., Olivier, A. J., Stewart, D., Hitzeroth, I. I., Rademacher, T., et al.
527 (2007). Optimization of human papillomavirus type 16 (HPV-16) L1 expression in
528 plants: Comparison of the suitability of different HPV-16 L1 gene variants and different
529 cell-compartment localization. *J. Gen. Virol.* 88(5), 1460-1469. doi:10.1099/vir.0.82718-
530 0.
- 531 Maliga, P., and Graham, I. (2004). Plant biotechnology: Molecular farming and metabolic
532 engineering promise a new generation of high-tech crops. *Curr. Opin. Plant Biol.* 7(2),
533 149-151. doi:/10.1016/j.pbi.2004.01.016.
- 534 Margolin, E. A., Strasser, R., Chapman, R., Williamson, A.-L., Rybicki, E. P., and Meyers, A.
535 E. (2020). Engineering the plant secretory pathway for the production of next-generation
536 pharmaceuticals. *Trends Biotechnol.* In press. doi:10.1016/j.tibtech.2020.03.004.
- 537 Neuman, B. W., Kiss, G., Kunding, A. H., Bhella, D., Baksh, M. F., Connelly, S., et al. (2011).
538 A structural analysis of M protein in coronavirus assembly and morphology. *J. Struct.*
539 *Biol.* 174(1), 11-22. doi:/10.1016/j.jsb.2010.11.021.
- 540 Okba, N., Muller, M., Li, W., Wang, C., GeurtsvanKessel, C., Corman, V., et al. (2020). SARS-
541 CoV-2 specific antibody responses in COVID-19 patients. *medRxiv*
542 2020.03.18.20038059. doi:/10.1101/2020.03.18.20038059.
- 543 Pogrebnyak, N., Golovkin, M., Andrianov, V., Spitsin, S., Smirnov, Y., Egolf, R., et al. (2005).
544 Severe acute respiratory syndrome (SARS) S protein production in plants: Development
545 of recombinant vaccine. *Proc. Natl. Acad. Sci. U.S.A.* 102(25), 9062-906.
546 doi:/10.1073/pnas.0503760102.
- 547 Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M.,
548 et al. (2020). Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,
549 population-based seroepidemiological study. *Lancet* 6736 (20), 1–11.
550 doi:10.1016/S0140-6736(20)31483-5.
- 551 Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A., et
552 al. (2020). The receptor binding domain of the viral spike protein is an immunodominant

- 553 and highly specific target of antibodies in SARS-CoV-2 patients. *Sci. Immunol.* 5(48),
554 eabc8413. doi:10.1126/sciimmunol.abc8413.
- 555 Randad, P. R., Pisanic, N., Kruczynski, K., Manabe, Y. C., Thomas, D., Pekosz, A., et al.
556 (2020). COVID-19 serology at population scale: SARS-CoV-2-specific antibody
557 responses in saliva. *medRxiv* 2020.05.24.20112300. doi:/10.1101/2020.05.24.20112300.
- 558 Remy, M. M., Alfter, M., Chiem, M. N., Barbani, M. T., Engler, O. B., and Suter-Riniker, F.
559 (2019). Effective chemical virus inactivation of patient serum compatible with accurate
560 serodiagnosis of infections. *Clin. Microbiol. Infect.* 25(7), 907-e7.
561 doi:10.1016/j.cmi.2018.10.016.
- 562 Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W., et al. (2020). Isolation of
563 potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small
564 animal model. *Science* eabc7520. doi:/10.1126/science.abc7520.
- 565 Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K. J. A., Hemmings, O., et al. (2020).
566 Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection.
567 *medRxiv* 2020.07.09.20148429. doi:10.1101/2020.07.09.20148429.
- 568 Shanmugaraj, B., Malla, A., and Phoolcharoen, W. (2020). Emergence of novel coronavirus
569 2019-nCoV: Need for rapid vaccine and biologics development. *Pathogens* 9(2), 148.
570 doi:10.3390/pathogens9020148.
- 571 Shanmugaraj, B., and Ramalingam, S. (2014). Plant expression platform for the production of
572 recombinant pharmaceutical proteins. *Austin J Biotechnol Bioeng* 1(6), 4. Available at:
573 [https://austinpublishinggroup.com/biotechnology-bioengineering/fulltext/ajbtbe-v1-](https://austinpublishinggroup.com/biotechnology-bioengineering/fulltext/ajbtbe-v1-id1026.php)
574 [id1026.php](https://austinpublishinggroup.com/biotechnology-bioengineering/fulltext/ajbtbe-v1-id1026.php).
- 575 Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., et
576 al. (2020). SARS-CoV-2 seroconversion in humans: A detailed protocol for a serological
577 assay, antigen production, and test setup. *Curr. Protoc. Microbiol.* 57(1), e100.
578 doi:10.1002/cpmc.100.
- 579 Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C. K., Zhou, J., et al. (2016). Epidemiology, genetic
580 recombination, and pathogenesis of coronaviruses. *Trends Microbiol.* 24(6), 490-502.
581 doi:10.1016/j.tim.2016.03.003.
- 582 Tan, W., Zhao, X., Ma, X., Wang, W., Niu, P., Xu, W., et al. (2020). A novel coronavirus
583 genome identified in a cluster of pneumonia cases - Wuhan, China 2019–2020. *China*
584 *CDC Wkly.* 2(4), 61-62. doi:/10.46234/ccdcw2020.017.
- 585 Tortorici, M. A., and Veessler, D. (2019). “Structural insights into coronavirus entry,” in
586 *Advances in Virus Research* (Academic Press Inc.) 105, 93–116.
587 doi:10.1016/bs.aivir.2019.08.002.
- 588 Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., et al. (2020).
589 SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable
590 for at least three months. *medRxiv* 2020.07.14.20151126.
591 doi:10.1101/2020.07.14.20151126.

- 592 Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., and Veerler, D. (2020).
593 Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 180(2),
594 281–292. doi:/10.1016/j.cell.2020.02.058.
- 595 Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., et al. (2020).
596 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*
597 367(6483), 1260-1263. doi:/10.1126/science.abb2507.
- 598 Yamamoto, T., Hoshikawa, K., Ezura, K., Okazawa, R., Fujita, S., Takaoka, M., et al. (2018).
599 Improvement of the transient expression system for production of recombinant proteins
600 in plants. *Sci. Rep.* 8(1), 1-10. doi:/10.1038/s41598-018-23024-y.
- 601 Yin, J., Li, G., Ren, X., and Herrler, G. (2007). Select what you need: A comparative evaluation
602 of the advantages and limitations of frequently used expression systems for foreign
603 genes. *J. Biotechnol.* 127(3), 335-347. doi:/10.1016/j.jbiotec.2006.07.012.
- 604 Zhao, R., Li, M., Song, H., Chen, J., Ren, W., Feng, Y., et al. (2020). Early detection of SARS-
605 CoV-2 antibodies in COVID-19 patients as a serologic marker of infection. *Clin. Infect.*
606 *Dis.* ciaa523. doi:/10.1093/cid/ciaa523.
- 607 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A novel coronavirus
608 from patients with pneumonia in China, 2019. *N. Engl. J. Med.* 382(8), 727–733.
609 doi:/10.1056/NEJMoa2001017.

610 **Table**

611

612 **Table 1: Characteristics of COVID-19 patients (n=77)**

613

Sex female, n (%)	42 (55)
Age (years) ^a	39 [29-50]
Time since positive PCR test (days) ^a	42 [29-52]
Disease severity, n (%) ^b	
<i>Asymptomatic</i>	5 (7)
<i>Mild</i>	23 (30)
<i>Moderate</i>	38 (49)
<i>Severe</i>	2 (3)

^a median and interquartile range

^b not available for n=9 participants

614

615

616 **Figure legends**

617 **Figure 1. Analysis of plant-expressed SARS-CoV-2 spike antigens after Protein A**
618 **purification.** (A) Coomassie-stained SDS-PAGE gel and (B) Western blot of S1-rabbit Fc
619 fusion protein (2 µg of concentrated elution fraction). Lines on the left indicate molecular
620 weight marker (Spectra Multicolor Broad range protein ladder) in kDa. The arrow indicates the
621 expected size for recombinant S1 protein (~140 kDa). (C) Coomassie-stained SDS-PAGE gel
622 and (D) Western blot of RBD-rabbit Fc fusion protein (5 µg of concentrated elution fraction).
623 Arrows indicate expected size for RBD-rabbit Fc conjugate (~100 kDa).

624

625 **Figure 2. Detection of IgG using plant-expressed SARS-CoV-2 spike antigens in COVID-**
626 **19 convalescent volunteers and pre-pandemic controls using an in-house ELISA.**
627 Reactivity to plant-expressed S1 (A) and RBD (B) in pre-pandemic samples from HIV-
628 uninfected individuals (n=31), HIV-infected individuals (n=27), and SARS-CoV-2 PCR
629 positive volunteers (n=77). Dotted lines indicate threshold for positivity, calculated as the mean
630 optical density (OD) + 2SD of the pre-pandemic samples. (C) Correlation of the OD values for
631 S1-specific IgG in our in-house ELISA and the commercial Euroimmun IgG S1 ELISA kit.
632 Statistical analyses were performed using a non-parametric Spearman rank correlation. Each
633 dot represents one individual.

634

635 **Figure 3. Semi-quantitative detection of S1- and RBD-specific IgG, IgM and IgA.** Two-
636 fold dilution series of sera for detection of S1-specific IgG (A), IgM (B), and IgA (C) and
637 RBD-specific IgG (D), IgM (E) and IgA (F). COVID-19 convalescent volunteers (n=20) are
638 indicated in red, and pre-pandemic controls (n=40) are indicated in black. (G-I) and (J-L), Data
639 from the same experiment as in (A-C) and (D-F), respectively, but plotted as area under the
640 curve (AUC). Horizontal lines represent median values. Dotted lines indicate the threshold for
641 positivity. Statistical analyses were performed using a Mann-Whitney U test. A p value of
642 <0.05 was considered statistically significant.

643

644 **Figure 4. The relationship between IgG, IgM and IgA responses to S1 and RBD SARS-**
645 **CoV-2 antigens.** (A) Proportions of COVID-19 convalescent volunteers mounting different
646 combinations of IgG, IgM and IgA specific for S1 (A) (n=19), and RBD (B) (n=20).
647 Relationship between S1-specific IgG and IgM (C) and IgG and IgA (D). Statistical analyses
648 were performed using a non-parametric Spearman rank correlation. Proportion of convalescent
649 volunteers with endpoint titers for IgG (E) and IgA (F) of 1:50, 1:100, 1:200, 1:400, 1:800,
650 1:1600.

651


652 **Figure 5. Detection of S1-specific antibodies in saliva.** Comparison of paired serum and
653 saliva S1-specific IgG (A) and IgA (B) (n=10). Dotted lines indicate the positivity threshold
654 for serum.

655

656 **Figure 6. Optimization of ELISA antigen coating concentration, coating buffer and**
657 **blocking buffer.** The effect of antigen coating concentration (1, 2 and 4 µg/ml) was tested for
658 (A) S1 and (B) RBD, using serum samples from SARS-CoV-2 positive convalescent
659 participants (n=7). Statistical analyses were performed using the Friedman test with Dunn's
660 test for multiple comparisons. (C) Comparison of phosphate buffered saline (PBS) and
661 bicarbonate buffer for coating viral antigens. Statistical analyses were performed using a
662 Wilcoxon matched pair's test. (D) The effect of different blocking solutions. Statistical analysis
663 was performed using the Friedman test with Dunn's test for multiple comparisons.

664

FIGURE 1




665

666

667


668

FIGURE 2



669


FIGURE 3



670

671


FIGURE 4



672


673

FIGURE 5



674

FIGURE 6



675